The move sets up a high-stakes fight over the drug, mifepristone, that could sharply curtail access to medication that is used in more than half of all pregnancy terminations in the United States.
Until it issues a decision, the Food and Drug Administration's approval of the drug remains in place, delaying the potential for an abrupt end to the medication.
[
add
]
[
|
|
...
]